Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations

Published on May 1, 2019in European Urology Oncology
· DOI :10.1016/J.EUO.2018.08.010
Paolo Gandellini25
Estimated H-index: 25
,
Nicola Casiraghi7
Estimated H-index: 7
(University of Trento)
+ 8 AuthorsNadia Zaffaroni66
Estimated H-index: 66
Sources
Abstract
Abstract Background Genomic characterization of prostate cancer (PCa) biopsies may improve criteria for the selection of patients suitable for active surveillance (AS). Objective To identify somatic genomic aberrations associated with adverse outcome as AS protocol exclusion indicators. Design, setting and participants Whole-exome sequencing profiles were generated for Gleason score (GS) = 3 + 3 biopsies obtained from 54 PCa patients enrolled in two AS protocols. Patients were selected as representative of a nonindolent population, consisting of 27 patients who dropped out from AS due to upgrading (ie, finding of GS > 3 + 3 at a follow-up biopsy) within 2 yr, and a potentially indolent population, consisting of 27 patients in AS for ≥4 yr without any evidence of reclassification. Outcome measurements and statistical analysis The genomic alteration landscape of core biopsies was analyzed using an integrated computational pipeline and correlated with patient reclassification due to upgrading. Results and limitations Of all the GS = 3 + 3 biopsies of the study cohort, 34% showed clear evidence of somatic copy number aberrations along the genome. Of these, 39% came from the potentially indolent and 61% from the nonindolent population. Single-nucleotide variants demonstrated low allelic fractions and included a common F133C mutation in the SPOP gene. The minimally altered genomic landscape of the study cohort presented a distinct set of monoallelic deletions, including on 8p, 13q, 16q, and 21q, and rare amplifications of 8q, which were observed in both AS patient populations. Concerning lesions typically associated with adverse outcome, PTEN deletions and MYC amplification, though observed in a small number of cases, were detected exclusively or preferentially, respectively, in nonindolent patients. Such molecular findings were confirmed by immunohistochemistry on the same tissue blocks. The small sample size and the retrospective nature of the analysis represent the main study limitations. Conclusions Genomic features enriched in aggressive tumors can be detected in GS = 3 + 3 core biopsies of AS patients. Patient summary PTEN and MYC alterations at the time of diagnosis would deserve investigation in larger cohorts of AS patients to assess their potential as biomarkers for a more precise/earlier identification of patients at risk of reclassification.
📖 Papers frequently viewed together
2018
20 Authors (Fabrice Andre, ..., Hervé Bonnefoi)
277 Citations
31 Citations
References21
Newest
#1Sophie Bruinsma (EUR: Erasmus University Rotterdam)H-Index: 13
#2Liying Zhang (Sunnybrook Health Sciences Centre)H-Index: 26
Last. Mieke Van Hemelrijck ('KCL': King's College London)H-Index: 36
view all 7 authors...
OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low‐risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow‐up for AS in this unique global AS database. PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwid...
36 CitationsSource
#1Joshua Armenia (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 28
#2Stephanie A. Wankowicz (Broad Institute)H-Index: 12
Last. Nikolaus Schultz (Broad Institute)H-Index: 4
view all 40 authors...
Comprehensive genomic characterization of prostate cancer has identified recurrent alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among others. However, larger and uniform genomic analysis may identify additional recurrently mutated genes at lower frequencies. Here we aggregate and uniformly analyze exome sequencing data from 1,013 prostate cancers. We identify and validate a new class of E26 transformation-specific (ETS)-fusion-negative tumors defined by mu...
321 CitationsSource
#1Alessandro Romanel (University of Trento)H-Index: 20
#2Tuo Zhang (NewYork–Presbyterian Hospital)H-Index: 41
Last. Francesca Demichelis (University of Trento)H-Index: 70
view all 4 authors...
Summary: Whole exome sequencing (WES) is widely utilized both in translational cancer genomics studies and in the setting of precision medicine. Stratification of individual's ethnicity is fundamental for the correct interpretation of personal genomic variation impact. We implemented EthSEQ to provide reliable and rapid ethnicity annotation from whole exome sequencing individual's data, validated it on 1000 Genome Project and TCGA data (2700 samples) demonstrating high precision, and finally ass...
12 CitationsSource
#1Adam G. Sowalsky (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 14
#2Haydn T. Kissick (Emory University)H-Index: 23
Last. Steven P. Balk (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 95
view all 12 authors...
Purpose: The molecular features that account for the distinct histology and aggressive biological behavior of Gleason pattern 4 (Gp4) versus Gp3 prostate cancer, and whether Gp3 tumors progress directly to Gp4, remain to be established. Experimental Design: Whole-exome sequencing and transcriptome profiling of laser capture–microdissected adjacent Gp3 and cribiform Gp4 were used to determine the relationship between these entities. Results: Sequencing confirmed that adjacent Gp3 and Gp4 were clo...
30 CitationsSource
#1C. MarenghiH-Index: 6
Last. Riccardo Valdagni (University of Milan)H-Index: 51
view all 34 authors...
PurposeTo evaluate the outcomes of active surveillance (AS) on patients with low-risk prostate cancer (PCa) and to identify predictors of disease reclassification.MethodsIn 2005, we defined an inst...
11 CitationsSource
#1Utku Lokman (UH: University of Helsinki)H-Index: 6
#2Andrew Erickson (UH: University of Helsinki)H-Index: 6
Last. Tuomas Mirtti (UH: University of Helsinki)H-Index: 26
view all 5 authors...
Abstract Background Active surveillance (AS) is an option for men with low-risk prostate cancer (PCa). PTEN and ERG have been considered as potential biomarkers of PCa progression and survival. Objective To study the role of ERG and PTEN status in the Prostate Cancer Research International: Active Surveillance (PRIAS) trial diagnostic biopsies (DBxs) in predicting surveillance discontinuation and adverse surgical findings in subsequent radical prostatectomy (RP). Design, setting, and participant...
26 CitationsSource
#1Leonard P. Bokhorst (Erasmus University Medical Center)H-Index: 12
#2Riccardo ValdagniH-Index: 51
Last. Monique J. Roobol (Erasmus University Medical Center)H-Index: 76
view all 7 authors...
Abstract Background The Prostate Cancer Research International Active Surveillance (PRIAS) study was initiated a decade ago to study the most optimal selection and follow-up of men on active surveillance (AS). Objective We report on 10 yr of follow-up of men on AS in the PRIAS study and evaluate if criteria used to recommend a switch to active treatment truly predict unfavorable outcome on subsequent radical prostatectomy (RP). Design, setting, and participants Men with low-risk prostate cancer ...
202 CitationsSource
#1Bruce J. Trock (Johns Hopkins University)H-Index: 86
#2Helen Fedor (Johns Hopkins University)H-Index: 14
Last. Angelo M. De Marzo (Johns Hopkins University)H-Index: 103
view all 10 authors...
Men who enter active surveillance because their biopsy exhibits only Gleason grade 3 (G3) frequently have higher grade tumor missed by biopsy. Thus, biomarkers are needed that, when measured on G3 tissue, can predict the presence of higher grade tumor in the whole prostate. We evaluated whether PTEN loss, chromosome 8q gain (MYC) and/or 8p loss (LPL) measured only on G3 cores is associated with un-sampled G4 tumor. A tissue microarray was constructed of prostatectomy tissue from patients whose p...
44 CitationsSource
#1Mark A. Rubin (Cornell University)H-Index: 157
#2Gabriele Girelli (University of Trento)H-Index: 5
Last. Francesca Demichelis (University of Trento)H-Index: 70
view all 3 authors...
Abstract Recommendations by the International Society of Urologic Pathology and 2016 World Health Organization blue book propose the use of a five-tiered prostate cancer (PCa) grading system. The five prognostic grade groupings (PGGs) ranging from 1 to 5 are defined as Gleason grades ≤6, 3+4, 4+3, 8, and >8, respectively. Recent work suggests that each group is associated with a distinct risk of biochemical PCa recurrence. In this study, we sought genomic support for PGGs using whole-exome and w...
54 CitationsSource
#1Jonathan I. Epstein (Johns Hopkins University)H-Index: 163
#2Michael J. Zelefsky (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 117
Last. Eric A. Klein (Cleveland Clinic)H-Index: 116
view all 17 authors...
Abstract Background Despite revisions in 2005 and 2014, the Gleason prostate cancer (PCa) grading system still has major deficiencies. Combining of Gleason scores into a three-tiered grouping (6, 7, 8–10) is used most frequently for prognostic and therapeutic purposes. The lowest score, assigned 6, may be misunderstood as a cancer in the middle of the grading scale, and 3+4=7 and 4+3=7 are often considered the same prognostic group. Objective To verify that a new grading system accurately produc...
736 CitationsSource
Cited By2
Newest
#1Paolo GandelliniH-Index: 25
Last. Nadia ZaffaroniH-Index: 66
view all 16 authors...
Active surveillance (AS) has evolved as a strategy alternative to radical treatments for very low risk and low-risk prostate cancer (PCa). However, current criteria for selecting AS patients are still suboptimal. Here, we performed an unprecedented analysis of the circulating miRNome to investigate whether specific miRNAs associated with disease reclassification can provide risk refinement to standard clinicopathological features for improving patient selection. The global miRNA expression profi...
Source
#1Miyaka Umemori (Jikei University School of Medicine)H-Index: 1
#2Morito Kurata (Tokyo Medical and Dental University)H-Index: 19
Last. Masanobu KitagawaH-Index: 33
view all 11 authors...
PVT1 is a long-noncoding RNA and is highly expressed in various cancers including prostate cancers with stabilizing MYC protein. To characterize the objective biological features of the different morphological components such as Gleason patterns (GP) in prostate cancer, biopsy specimens containing only single pure GP (GP3, GP4, GP5) are used to analyze the relationship between PVT1 expression and MYC protein expression. The expressions of PVT1 and MYC were analyzed by quantitative PCR and the la...
5 CitationsSource